Approval “is an important stage in public health in acute pain management”, Jacqueline Corrigan-Curay, JD, MD, acting director of the Center for Drug Evaluation and Research of the FDA, in a press release. “A new non -opioid analgesic therapeutic class for acute pain offers the possibility of mitigating certain risks associated with the use of an opioid for pain and provides patients with another treatment option.”
The company behind the drug, Vertex, said that a 50 mg pill that works for 12 hours will have a wholesale cost of $ 15.50, which makes the daily cost of $ 31 and the weekly cost of $ 217 . The cost is higher than inexpensive generic opioids. However, a report from the Institute for the Clinical and Economic Review in December estimated that suzetrigine would be “slightly economical” compared to opioids if the price was set at $ 420 per week, given the medicine’s ability to avoid Cases of opioid dependence.
In a press release, Reshma Kewalramani, CEO and President of Vertex, deceived approval as a “historic step for the 80 million people in America who prescribed a drug for a moderate to severe acute pain each year … ( W) I have the possibility of modifying the paradigm of acute pain management and establishing a new standard of care.